S&P 500   3,296.86 (+0.07%)
DOW   26,701.73 (+0.14%)
QQQ   269.86 (+0.18%)
AAPL   440.35 (+1.06%)
MSFT   212.43 (-1.90%)
FB   250.86 (-0.44%)
GOOGL   1,477.49 (-0.36%)
AMZN   3,136.89 (+0.80%)
NVDA   446.66 (+1.42%)
CGC   19.13 (+0.37%)
BABA   259.77 (+0.71%)
TSLA   1,494.13 (+0.61%)
MU   51.28 (+1.77%)
GE   6.15 (+0.65%)
AMD   82.84 (+6.64%)
T   30.02 (+1.35%)
F   6.79 (+1.49%)
ACB   10.42 (+1.36%)
GILD   70.82 (-1.27%)
NFLX   506.73 (+1.63%)
DIS   116.79 (+0.38%)
BAC   24.91 (-0.32%)
BA   164.85 (+1.59%)
S&P 500   3,296.86 (+0.07%)
DOW   26,701.73 (+0.14%)
QQQ   269.86 (+0.18%)
AAPL   440.35 (+1.06%)
MSFT   212.43 (-1.90%)
FB   250.86 (-0.44%)
GOOGL   1,477.49 (-0.36%)
AMZN   3,136.89 (+0.80%)
NVDA   446.66 (+1.42%)
CGC   19.13 (+0.37%)
BABA   259.77 (+0.71%)
TSLA   1,494.13 (+0.61%)
MU   51.28 (+1.77%)
GE   6.15 (+0.65%)
AMD   82.84 (+6.64%)
T   30.02 (+1.35%)
F   6.79 (+1.49%)
ACB   10.42 (+1.36%)
GILD   70.82 (-1.27%)
NFLX   506.73 (+1.63%)
DIS   116.79 (+0.38%)
BAC   24.91 (-0.32%)
BA   164.85 (+1.59%)
S&P 500   3,296.86 (+0.07%)
DOW   26,701.73 (+0.14%)
QQQ   269.86 (+0.18%)
AAPL   440.35 (+1.06%)
MSFT   212.43 (-1.90%)
FB   250.86 (-0.44%)
GOOGL   1,477.49 (-0.36%)
AMZN   3,136.89 (+0.80%)
NVDA   446.66 (+1.42%)
CGC   19.13 (+0.37%)
BABA   259.77 (+0.71%)
TSLA   1,494.13 (+0.61%)
MU   51.28 (+1.77%)
GE   6.15 (+0.65%)
AMD   82.84 (+6.64%)
T   30.02 (+1.35%)
F   6.79 (+1.49%)
ACB   10.42 (+1.36%)
GILD   70.82 (-1.27%)
NFLX   506.73 (+1.63%)
DIS   116.79 (+0.38%)
BAC   24.91 (-0.32%)
BA   164.85 (+1.59%)
S&P 500   3,296.86 (+0.07%)
DOW   26,701.73 (+0.14%)
QQQ   269.86 (+0.18%)
AAPL   440.35 (+1.06%)
MSFT   212.43 (-1.90%)
FB   250.86 (-0.44%)
GOOGL   1,477.49 (-0.36%)
AMZN   3,136.89 (+0.80%)
NVDA   446.66 (+1.42%)
CGC   19.13 (+0.37%)
BABA   259.77 (+0.71%)
TSLA   1,494.13 (+0.61%)
MU   51.28 (+1.77%)
GE   6.15 (+0.65%)
AMD   82.84 (+6.64%)
T   30.02 (+1.35%)
F   6.79 (+1.49%)
ACB   10.42 (+1.36%)
GILD   70.82 (-1.27%)
NFLX   506.73 (+1.63%)
DIS   116.79 (+0.38%)
BAC   24.91 (-0.32%)
BA   164.85 (+1.59%)
Log in

NASDAQ:MBVXMabvax Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.02
0.00 (0.00 %)
(As of 03/19/2020)
Add
Compare
Today's Range
$0.02
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.38
$1.15
52-Week Range
$0.10
Now: $0.02
$2.55
Volume1,333 shs
Average Volume31,620 shs
Market Capitalization$212,865.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBVX
Previous SymbolOTCMKTS:TELKD
CUSIPN/A
Phone858-259-9405

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$212,865.00
Next Earnings DateN/A
OptionableNot Optionable

Receive MBVX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBVX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mabvax Therapeutics (NASDAQ:MBVX) Frequently Asked Questions

How were Mabvax Therapeutics' earnings last quarter?

Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($1.62) earnings per share (EPS) for the quarter.
View Mabvax Therapeutics' earnings history
.

When did Mabvax Therapeutics' stock split? How did Mabvax Therapeutics' stock split work?

Mabvax Therapeutics's stock reverse split on the morning of Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 15th 2018. An investor that had 100 shares of Mabvax Therapeutics stock prior to the reverse split would have 33 shares after the split.

Has Mabvax Therapeutics been receiving favorable news coverage?

News stories about MBVX stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mabvax Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about Mabvax Therapeutics
.

Who are some of Mabvax Therapeutics' key competitors?

What other stocks do shareholders of Mabvax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mabvax Therapeutics investors own include Immunomedics (IMMU), GW Pharmaceuticals PLC- (GWPH), Athersys (ATHX), Dollar General (DG), Gilead Sciences (GILD), Zynerba Pharmaceuticals (ZYNE), Depomed (DEPO), Celgene (CELG), Galectin Therapeutics (GALT) and Protalix Biotherapeutics (PLX).

Who are Mabvax Therapeutics' key executives?

Mabvax Therapeutics' management team includes the following people:
  • Mr. John David Hansen, Chairman, Pres & CEO (Age 67)
  • Prof. Philip O. Livingston, Co-Founder, Chief Science Officer & Director (Age 75)
  • Mr. Gregory P. Hanson C.M.A., M.B.A., MBA, CMA, Chief Financial Officer (Age 71)
  • Dr. Paul W. Maffuid, Exec. VP of R&D (Age 63)
  • Dr. Paul F. Resnick, VP & Chief Bus. Officer (Age 61)

What is Mabvax Therapeutics' stock symbol?

Mabvax Therapeutics trades on the NASDAQ under the ticker symbol "MBVX."

What is Mabvax Therapeutics' stock price today?

One share of MBVX stock can currently be purchased for approximately $0.02.

How big of a company is Mabvax Therapeutics?

Mabvax Therapeutics has a market capitalization of $212,865.00.

What is Mabvax Therapeutics' official website?

The official website for Mabvax Therapeutics is www.mabvax.com.

How can I contact Mabvax Therapeutics?

Mabvax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.